Eurocor - Life Sciences Technologies Interventional Cardiology Devices Endovascular Therapies

Dediacted to Your heart.
Life Sciences Technology.
Coronary stent technologies and special cardiovascular and endovascluar devices made in Europe for the world.

Successful Eurocor symposium about drug-eluting balloons at CIRSE in Munich

Date: 2011/09/14

International Eurocor Symposium about Drug-Eluting Balloons for endovascular – Update 2011 and Perspectives: Next generation coating



Eurocor, the Bonn (Germany) based specialist for drug-eluting balloon technology is present at the annual meeting of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) in Munich September 10 – 14, 2011. Eurocor had a successful and very well visited international symposium titled Drug-Eluting Balloons – Update 2011 and Perspectives: Next generation coating. Chairmen were Prof. Josef Tacke (Passau, Germany) and Prof. Gunnar Tepe (Rosenheim, Germany). More than 500 physicians and visitors gathered at the congress to hear the latest news about drug-eluting balloon technology.

Prof. Tacke started with the challenges of treatment in the superficial femoral artery (SFA) and below-the-knee (BTK) lesions. He referred to the still unsolved problems of high restenosis rates in those areas after treatment of plain old balloon angioplasty (POBA) or stenting in patients with peripheral artery disease (PAD).

Prof. Tepe (Rosenheim, Germany) highlighted initially in his presentation that many companies are working on DEB concepts but the major difference of those is the drug carrier which transports the paclitaxel into the vessel wall. Furthermore he presented the current stage of the Eurocor peripheral trial program. He concluded that DEBs have already shown clinical benefits in daily practice and will definitely change the radiologist’s and patient’s life now and in future.

During the Eurocor symposium Prof. Lammer (Vienna, Austria) gave a lecture about the TASC II B guidelines titled “endovascular first”. He presented the current stage of the overwork and pointed out that the endovascular treatment of patients is the first choice in TASC A to D lesions in the SFA. In the future there will be also TASC recommendations for the treatment of infrapopliteal lesions for patients with Critical Limb Ischemia (CLI).
Surgical revascularation should only be reserved for specific challenging scenarios BTK or following unsatisfactory endovascular results, he closed.

Dr. Manzi from the Policlinic Abano (Abano Terme, Italy) provided a lecture about the perspective of drug-eluting balloons, especially for below the knee (BTK) interventions. The outcomes of POBA treatments are limited especially in long occluded BTK lesions. The healing time in diabetic foot ulcers is long and therefore a prevention of restenosis in this wound healing period is crucial. In conclusion he stated that DEB could be a potential solution to treat BTK restenosis during the wound healing period.

Kirsten Peters, from the University Hospital Rostock presented the evaluation of shellac as suitable coating of intravascular devices. The new coating concept of Eurocors DEBs is homogeneous and non crystalline. It has been proven that shellac is non-toxic and shows no influence on the metabolic activity of endothelial and smooth muscle cells.

Eurocor is providing CE certified drug-eluting balloons (DEB) for endovascular and cardiovascular procedures. Eurocor offers a full dedicated product line for BTK artery treatment, FREEWAY™ 014 for the treatment of patients with CLI. Eurocor recently launched FREEWAY™ 035, especially designed to treat atherosclerosis in the SFA. The unique coating concept of FREEWAY™ and DIOR® DEB allows a safe and efficient use, without considerable washout effect.

International Eurocor Symposium about Drug-Eluting Balloons for endovascular